Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NPAS2 antisense RNA 1 (NPAS2-AS1) is presumed to be an antisense non-coding RNA transcript complementary to the NPAS2 gene locus. There is currently no peer-reviewed functional data, molecular characterization, or recognition in gene/protein/ncRNA nomenclature authorities supporting an established role for NPAS2-AS1 in physiology, disease, or as a therapeutic target. All available research and annotation focus instead on the NPAS2 protein itself—a basic helix-loop-helix-PAS domain transcription factor crucial for circadian rhythm regulation and with emerging roles in cancer biology, metabolism, and neurobehavioral processes[2][5][6]. No data are available regarding the biological functions, disease associations, or druggability of the NPAS2-AS1 transcript. Clarification: If you are seeking information on "NPAS2," the canonical circadian transcription factor, detailed annotations are available and supported by the literature[2][5][6]. If you specifically require antisense RNA annotations, this transcript would be considered noncanonical, and there is insufficient information for any structured drug-target analysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NPAS2 antisense RNA 1 (NPAS2-AS1).